General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Half-Life (Normalesrd) Hours
23-40/No data
Plasma Protein Binding %
75
Volume Of Distribution L/Kg
200-300
Dose For Normal Renal Function
10-15 mg/m2 qd-qwk
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Ehninger G, Schuler U, Proksch B, Zeller KP, Blanz J. Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet. 1990; 18: 365-80. [PMID: 2185907] / Faulds D, Balfour JA, Chrisp P, Langtry HD. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 1991; 41: 400-49. [PMID: 1711446] / Savaraj N, Lu K, Manuel V, Loo TL. Pharmacology of mitoxantrone in cancer patients. Cancer Chemother Pharmacol. 1982; 8: 113-7. [PMID: 7094196]